Fatty liver disease is no longer a death sentence waiting to happen, and new research is showing why. Metabolic dysfunction-associated steatotic liver disease, or MASLD (formerly called non-alcoholic fatty liver disease), now affects roughly one in three adults worldwide. But doctors are moving beyond simply telling patients to lose weight. A wave of new medications and emerging research into compounds like CBD are targeting the underlying metabolic problems that drive the disease, offering real hope for the millions living with excess liver fat.

What Is MASLD and Why Is It Becoming So Common?

MASLD is characterized by fat accumulation in more than 5 percent of liver cells in people who drink little or no alcohol. The condition exists on a spectrum. Simple steatosis means fat sitting quietly in the liver with minimal inflammation. But when fat is joined by inflammation and liver cell damage, it becomes metabolic dysfunction-associated steatohepatitis, or MASH, which can progress to fibrosis (scarring), cirrhosis, and even liver cancer.

The key insight from recent research is that MASLD is not just a liver problem; it is a metabolic problem, tightly linked to obesity, type 2 diabetes, insulin resistance, and metabolic syndrome. This distinction matters because it changes how doctors approach treatment. Rather than focusing only on the liver, new therapies target the metabolic drivers that cause fat to accumulate in the first place.

How Are Doctors Identifying Who Needs Treatment?

One of the biggest challenges with MASLD is that most people with the condition will never develop serious liver disease. The real danger lies in identifying the minority who develop significant liver scarring, called fibrosis. Fibrosis, not the fat itself, is what predicts future risks of cirrhosis, liver failure, liver cancer, and liver-related death.

Doctors now use a simple blood test called the FIB-4 score to estimate fibrosis risk. The score uses age, two liver enzymes called AST and ALT, and platelet count to determine who might have advanced scarring. However, a critical finding has emerged: many patients with significant liver fibrosis, and even some with cirrhosis, have liver enzyme levels that appear completely normal on standard blood tests. This means a normal ALT result does not rule out serious liver disease.

Abnormal liver tests should usually be confirmed with repeat testing and assessment for common causes. Useful investigations often include blood tests to exclude hepatitis B, hepatitis C, hemochromatosis, and autoimmune liver disease. Ultrasound can detect liver fat but cannot reliably determine the degree of fibrosis. Elastography, which measures liver stiffness, provides a better picture of scarring.

What New Medications Are Showing Promise?

At the American Diabetes Association Scientific Sessions in 2026, hepatologists presented an overview of peroxisome proliferator-activated receptor, or PPAR, agonists, a new class of drugs that target multiple pathways involved in MASLD and MASH. These medications work by regulating genes involved in glucose metabolism, lipid metabolism, inflammation, and energy balance.

Pioglitazone was the first PPAR agonist to demonstrate that targeting insulin resistance can improve liver histology in MASH. In the 96-week PIVENS trial, pioglitazone showed significant histologic improvement without worsening fibrosis, with 34 percent of patients showing improvement compared to 19 percent on placebo. However, pioglitazone has limitations, including weight gain, fluid retention, and increased fracture risk with long-term use.

Saroglitazar, a dual PPAR-alpha and PPAR-gamma agonist, combines metabolic and hepatic benefits. It was first approved in India in 2013 for diabetic dyslipidemia and hypertriglyceridemia in patients with type 2 diabetes, then approved in 2020 for MASLD and MASH. Recent Phase 4 data from India showed that patients with MASH who received saroglitazar for 52 weeks experienced significant improvements in liver stiffness, hepatic steatosis, liver enzymes, blood sugar control, and triglyceride levels, while body weight and BMI remained largely stable.

Lanifibranor is a pan-PPAR agonist, activating all three PPAR receptors simultaneously. By targeting all three receptors, it addresses the major pathological components of MASH, including steatosis, inflammation, and fibrosis. The Phase IIb NATIVE trial has demonstrated early promise, and the Phase III NaTiV3 trial is currently underway.

What Does the Latest Research Show About CBD and Fatty Liver?

Beyond pharmaceutical approaches, a landmark 2026 study from Hebrew University of Jerusalem published in the British Journal of Pharmacology examined whether cannabidiol, or CBD, and cannabigerol, or CBG, could help reduce liver fat. In a mouse model of diet-induced obesity and MASLD, researchers tested daily CBD and CBG treatment over four weeks.

The results were striking. Both compounds reduced hepatic triglycerides, improved blood sugar handling, normalized blood fat profiles, and restored lysosomal function, which are the cellular recycling centers that break down and clear fat. The researchers identified a novel mechanism: CBD and CBG boosted energy buffering in the liver and restored the activity of cathepsin enzymes, which are critical for lysosomal lipid degradation. In plain terms, the compounds helped liver cells process and clear fat more efficiently.

A 2026 study in the Journal of Cannabis Research examined CBD's effect on inflammation, finding that CBD supplementation reduced the pro-inflammatory n-6 pathway and shifted the balance toward anti-inflammatory n-3 fatty acids, suggesting it could help prevent progression from MASLD to the more dangerous MASH. A related 2026 study in Scientific Reports looked at cannabidiolic acid, or CBDA, in rats with MASLD, finding that it reduced the expression of fatty acid transporters and lowered harmful lipid accumulation.

The takeaway from CBD research is that the compound's effects on the liver and on metabolism appear to reinforce each other. Better blood sugar control reduces the metabolic stress driving fat accumulation, while better liver fat handling improves overall metabolic health.

How Should Treatment Decisions Be Made?

As MASLD and MASH management evolves, experts emphasize that treatment should extend beyond a single approach. The MASH treatment landscape is rapidly expanding, with multiple therapies already available or in late-stage clinical development. Since MASLD and MASH are driven by multiple pathogenic pathways, no single therapy is expected to address every aspect of disease progression.

Instead, therapies with complementary mechanisms, including PPAR agonists, are likely to become part of combination treatment strategies aimed at improving histological response while optimizing cardiometabolic and liver outcomes. Clinicians should actively identify patients with type 2 diabetes at high risk of advanced fibrosis and make treatment decisions that extend beyond glycemic control to include liver health.

Steps to Take If You Have Abnormal Liver Tests

• Confirm the Results: Abnormal liver tests should usually be confirmed with repeat testing before assuming they indicate liver disease, as many abnormalities are harmless or reversible.
• Assess Common Causes: Work with your doctor to review all prescription medications, over-the-counter products, supplements, and complementary medicines, as many can affect liver tests.
• Evaluate Alcohol Use: Accurate alcohol assessment is important because metabolic fatty liver disease, alcohol-related liver disease, and other forms can overlap, and intake is often underestimated.
• Get Fibrosis Assessment: If MASLD is suspected, ask your doctor about fibrosis assessment tools like the FIB-4 score or elastography, since fibrosis stage, not fat amount, determines long-term risk.
• Address Metabolic Risk Factors: Work on weight loss, better metabolic health, and treatment of contributing factors like type 2 diabetes and insulin resistance, as these improvements can help reduce fibrosis.

The encouraging news is that fibrosis, particularly early-stage fibrosis, may improve with weight loss, better metabolic health, and treatment of contributing factors. For most patients, there is no single liver medication that replaces weight loss and metabolic health, but new PPAR agonists and emerging research into compounds like CBD are expanding the toolkit available to doctors and patients fighting this increasingly common disease.